PRESS RELEASE
By: News Direct
July 3, 2024
This Biotech Just Cleared A Big FDA Hurdle In Its Quest To Improve ADHD Treatment
By Johnny Rice, Benzinga
Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), were recently guests on Benzinga’s All Access.
Cingulate is a biotechnology company developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, relieving the pill burden many people with chronic conditions suffer.
Cingulate was just given clearance by the FDA to seek full approval for its lead candidate, CTx-1301.
Watch the full interview here:
Featured photo by Hal Gatewood on Unsplash.
Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Contact DetailsBenzinga
+1 877-440-9464
Company WebsiteView source version on newsdirect.com: https://newsdirect.com/news/this-biotech-just-cleared-a-big-fda-hurdle-in-its-quest-to-improve-adhd-treatment-341277340
This press release is distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is This Biotech Just Cleared A Big FDA Hurdle In Its Quest To Improve ADHD Treatment.
